Compare FRGT & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRGT | VIVS |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | Mexico | United States |
| Employees | N/A | 9 |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 2.5M |
| IPO Year | 2021 | N/A |
| Metric | FRGT | VIVS |
|---|---|---|
| Price | $5.22 | $0.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 87.5K | ★ 114.1K |
| Earning Date | 05-20-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 96.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,728,922.00 | N/A |
| Revenue This Year | $371.03 | $42.38 |
| Revenue Next Year | N/A | $15.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.78 |
| 52 Week High | $5.90 | $5.30 |
| Indicator | FRGT | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 65.75 | 35.05 |
| Support Level | $0.80 | $0.78 |
| Resistance Level | $5.90 | $1.88 |
| Average True Range (ATR) | 0.52 | 0.14 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 95.21 | 10.57 |
Freight Technologies Inc is a technology company developing solutions to optimize and automate the supply chain process. Along with its subsidiary, Freight App, Inc, the group is focused on making shipping transparent and efficient. Fr8App provides carriers with increased growth opportunities and shippers with flexibility, visibility, and simplicity for the once-complex process of international over-the-road (OTR) shipping. The company uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via technologies such as live pricing and real-time tracking, digital freight marketplace, broker, transportation management, fleet management, and committed capacity solutions.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.